CANNABIDIOL: A PROMISE FOR ANXIETY? EXPLORING EFFICACY, PSYCHOLOGICAL IMPACTS AND SCIENTIFIC EVIDENCE
DOI:
https://doi.org/10.63330/armv1n5-001Keywords:
Cannabidiol, Anxiety Disorders, Cognitive Behavioral Therapy, Central Nervous SystemAbstract
This study analyzes the therapeutic potential of cannabidiol (CBD) in the treatment of anxiety disorders, exploring its possible synergy with Cognitive-Behavioral Therapy (CBT) in the Brazilian context. Based on a systematic review of the literature, conducted on the BVS, SciELO, PubMed and NCBI databases, scientific articles were selected that investigate the mechanisms of action of CBD, its effects on modulating the endocannabinoid system and its efficacy as an adjuvant to CBT. The results suggest that CBD may be a promising alternative to conventional treatments, modulating neurochemical responses associated with anxiety, although methodological limitations and the need for more robust clinical trials are highlighted. The paper also discusses the implications of these findings for clinical practice, reinforcing the importance of integrative approaches in the management of anxiety.
References
ABREU, R. R. S. de; PASSOS, M. A. N. O uso de canabidiol como tratamento do autismo. Revista JRG de Estudos Acadêmicos, v. 6, n. 12, p. 436-448, 2023. Disponível em: https://doi.org/10.5281/zenodo.7858939. Acesso em: 20 jun. 2025.
BADOLATO, C. J.; LYNCH, E. A.; ARNOLD, J. C.; MCGREGOR, I. S.; BOWEN, M. T. Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: exploration of other potential receptor targets. British Journal of Pharmacology, v. 1–26, 2025. DOI: 10.1111/bph.70070. Acesso em: 21 jun. 2025.
BAKKER, J. Cannabidiol: anxiety relief or fool’s gold? 2025. 58 f. Trabalho de Conclusão de Curso (Especialização em Physician Assistant Studies) – Department of Physician Assistant Studies, University of North Dakota, Grand Forks, 2025. Disponível em: https://commons.und.edu/pas-grad-papers/220. Acesso em: 21 jun. 2025.
BATTISTIN, L.; MOYA, L. F. A.; FERREIRA, L. V. de O.; BRAZ, A. M. M.; CARVALHO, M. de; GOLIM, M. de A.; AMORIM, R. M. In vitro immunomodulatory effects of equine adipose tissue-derived mesenchymal stem cells primed with a cannabidiol-rich extract. International Journal of Molecular Sciences, v. 26, p. 4208, 2025. Disponível em: https://www.mdpi.com/1422-0067/26/7/4208. Acesso em: 20 jun. 2025.
CECILIO, S. A. J.; OLIVEIRA JÚNIOR, J. O. de. Cannabis versus neuromoduladores na dor crônica. Brazilian Journal of Pain, São Paulo, v. 6, supl. 2, p. S146-S152, 2023. Acesso em: 20 jun. 2025.
CHO, A. Y. H. et al. Motifs in natural products as useful scaffolds to obtain novel benzo[d]imidazole-based cannabinoid type 2 (CB2) receptor agonists. International Journal of Molecular Sciences, Basel, v. 24, p. 10918, 30 jun. 2023. Disponível em: https://doi.org/10.3390/ijms241310918. Acesso em: 19 jun. 2025.
CRIPPA, J. A. S. et al. Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930–March 9, 2023) and his legacy for Brazilian pharmacology. Brazilian Journal of Psychiatry, São Paulo, v. 45, n. 3, p. 201-202, maio/jun. 2023. DOI: 10.47626/1516-4446-2023-0047. Acesso em: 19 jun. 2025.
FERREIRA, E. M.; LOMBARDO, M. Produtos de Cannabis para fins medicinais no Brasil: um panorama farmacêutico e sanitário de 2020 a 2024. Research, Society and Development, v. 14, n. 2, e12314248308, 2025. Disponível em: http://dx.doi.org/10.33448/rsd-v14i2.48308. Acesso em: 21 jun. 2025.
FRANÇA, G. de O. et al. Uso terapêutico de óleo de Cannabis em pacientes com insônia e ansiedade: uma revisão. Brazilian Journal of Health Review, Curitiba, v. 6, n. 6, p. 28321-28338, nov./dez. 2023. DOI: 10.34119/bjhrv6n6-139. Acesso em: 21 jun. 2025.
GARCÍA-GUTIÉRREZ, M. S.; DE PRADO, A.; MANZANARES, J. Cannabidiol: a potential therapeutic drug for the ailments in neuropsychiatry. Biomolecules, v. 10, p. 1-34, nov. 2020. DOI: 10.3390/biom10111575. Acesso em: 21 jun. 2025.
GARAKANI, A. et al. Current pharmacotherapy options for anxiety disorders and obsessive-compulsive and related disorders. Frontiers in Psychiatry, v. 11, p. 595584, 23 dez. 2020. Disponível em: https://www.frontiersin.org/articles/10.3389/fpsyt.2020.595584/full. Acesso em: 21 jun. 2025.
HAN, K. et al. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis. Psychiatry Research, v. 339, p. 116049, 2024. Disponível em: [link]. Acesso em: 19 jun. 2025.
LIU, J. et al. Estimation of the global disease burden of depression and anxiety between 1990 and 2044: an analysis of the Global Burden of Disease Study 2019. Healthcare, Basel, v. 12, p. 1721, 2024. Disponível em: https://doi.org/10.3390/healthcare12171721. Acesso em: 20 jun. 2025.
LISBOA, I. B.; COLLI, L. F. M. Atenção farmacêutica no uso de benzodiazepínicos e outros psicofármacos no tratamento de transtornos de ansiedade e pânico por jovens atualmente no município de Nova Iguaçu. Revista Ibero-Americana de Humanidades, Ciências e Educação (REASE), São Paulo, v. 7, n. 10, p. 1299-1310, out. 2021. DOI: 10.51891/rease. v7i10.2663. Acesso em: 20 jun. 2025.
MAGALHÃES, A. P. G. de O. et al. Transtornos de ansiedade na emergência psiquiátrica: diagnóstico e conduta. Brazilian Journal of Health Review, Curitiba, v. 8, n. 1, p. 01-15, jan. /fev. 2025. DOI: 10.34119/bjhrv8n1-522. Acesso em: 20 jun. 2025.
MEDEIROS, M. G. A atuação dos três poderes na (des)regulamentação da cannabis terapêutica: reflexões à luz da Lei de Drogas e do direito constitucional à saúde. 2025. 70 f. Trabalho de Conclusão de Curso (Graduação em Direito) – Centro de Ciências Jurídicas, Universidade Federal da Paraíba, João Pessoa, 2025.
NICOARA, C.; FEZZA, F.; MACCARRONE, M. FAAH modulators from natural sources: a collection of new potential drugs. Cells, Basel, v. 14, n. 551, p. 1-27, 5 abr. 2025. Disponível em: https://doi.org/10.3390/cells14070551. Acesso em: 19 jun. 2025.
RODRIGUES, M. A. C. Contribuições do sistema nervoso central no processo de aprendizagem. Revista Psicologia Unime, v. 5, n. 2, p. 13-24, 2022. DOI: 10.38087/2595.8801.150. Acesso em: 19 jun. 2025.
SAMPAIO, M. de F. dos S. et al. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson’s disease and in comorbidity with psychiatric disorders. Basic & Clinical Pharmacology & Toxicology, v. 134, p. 574–601, 2024. DOI: 10.1111/bcpt.13997. Acesso em: 19 jun. 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Paulo Henrique Piccolo, Rachel de Oliveira Rabelo, Isa Carla Alves de Sousa, Melissa Cardoso Deuner, Grazieli Aparecida Huppes, Olyver Tavares de Lemos Santos , Heron Flores Nogueira, Gregório Otto Bento de Oliveira, Johnata Spindola de Ataides, Luciene Alves dos Santos Silva (Autor)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
